Back to today’s briefing

Story perspectives

FDA Approves Atzumi Nasal Powder for Migraine Relief

5/3/2025

29 5

Summary

Story summary

The FDA has greenlit Satsuma's STS101 nasal powder, Atzumi, for acute migraine relief. This innovative treatment enables patients to self-administer up to two doses in a day, providing much-needed flexibility. While some may experience rhinitis or nausea, Atzumi's user-friendly design promises to improve the lives of migraine sufferers across the U.S.

1 of 1

Story summary

The FDA has greenlit Satsuma's STS101 nasal powder, Atzumi, for acute migraine relief. This innovative treatment enables patients to self-administer up to two doses in a day, providing much-needed flexibility. While some may experience rhinitis or nausea, Atzumi's user-friendly design promises to improve the lives of migraine sufferers across the U.S.